Viatris downsizes; Biovectra partners with Acuitas; Pfizer’s Hospira recalls injections; WuXi secures two new deals
05 Oct 2023
Executive Change
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls, and more.
This week we saw multiple CDMO leadership appointments, as well as Biovectra accessing Acuitas Therapeutics’ technology to develop therapies at its new facility in Canada.
We also zero in on Viatris selling parts of its business in a move that will have it focused as an eye care company, as well as WuXi Biologics securing two separate deals with PharmaEssentia and IMIDomics.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.